FINTEPLA Drug Patent Profile

Which patents cover Fintepla, and what generic alternatives are available?

Fintepla is a drug marketed by Ucb Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-five patent family members in twenty-eight countries.

The generic ingredient in FINTEPLA is fenfluramine hydrochloride. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fenfluramine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Fintepla

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 29, 2038. This may change due to patent challenges or generic licensing.

There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for FINTEPLA

International Patents:	145
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	2
Patent Applications:	4,191
Drug Prices:	Drug price information for FINTEPLA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FINTEPLA
What excipients (inactive ingredients) are in FINTEPLA?	FINTEPLA excipients list
DailyMed Link:	FINTEPLA at DailyMed

See drug prices for FINTEPLA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FINTEPLA

Constraining patent/regulatory exclusivity:

10,452,815*PED

NDA:

212102

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FINTEPLA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
UCB BIOSCIENCES, Inc.	Phase 3
Zogenix, Inc.	Phase 3
University Health Network, Toronto	Phase 3

See all FINTEPLA clinical trials

Paragraph IV (Patent) Challenges for FINTEPLA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FINTEPLA	Oral Solution	fenfluramine hydrochloride	2.2 mg/mL	212102	1	2021-06-21

US Patents and Regulatory Information for FINTEPLA

FINTEPLA is protected by fourteen US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,452,815.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	11,759,440*PED				Y
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	9,603,814*PED				Y
Ucb Inc	FINTEPLA	fenfluramine hydrochloride	SOLUTION;ORAL	212102-001	Jun 25, 2020		RX	Yes	Yes	9,549,909*PED				Y

International Patents for FINTEPLA

When does loss-of-exclusivity occur for FINTEPLA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

New Zealand

Russian Federation

Saudi Arabia

Singapore

South Africa

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FINTEPLA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015326472
Australia	2020202655
Brazil	112017006219
Canada	2962367

FINTEPLA (fenfluramine) Market Dynamics and Financial Trajectory: Revenue Drivers, Pricing, Competition, and Exclusivity Risk

Last updated: July 22, 2026

FINTEPLA (fenfluramine) has moved from a late-stage launch phase into a volume-and-payer–driven growth cycle anchored in Dravet syndrome and Lennox-Gastaut syndrome (LGS) use, with revenue durability dependent on pediatric neurology share, payer coverage for long-term therapy, and competitive displacement risk from antiepileptic drugs and any future behavioral/adjunct therapies. The financial trajectory is shaped by (1) uptake within Dravet, (2) expanding penetration in LGS with evolving guideline adoption, (3) rebate intensity and net-price compression in managed care, (4) regulatory and manufacturing continuity, and (5) patent and exclusivity milestones that govern generic and branded entry risk.

What drove FINTEPLA (fenfluramine) sales growth in Dravet and Lennox-Gastaut?

FINTEPLA is positioned in two high-unmet-need, chronic pediatric epilepsies. Its commercial dynamic is less “switch-and-save” and more “patient capture and retention,” given ongoing dosing and the expectation of durable seizure reduction in eligible patients.

Dravet syndrome: the initial anchor indication

Dravet remains the principal early-market volume driver because it supports:

• High neurologist commitment for rare-drug pathways
• Faster patient onboarding once criteria are established in specialty practices
• Lower switching probability after stabilization

Commercial impact typically concentrates in three levers:

• Prescriber conversion: pediatric epilepsy centers add fenfluramine to regimen plans
• Retention: continued dosing in responders reduces churn
• Access pathway success: coverage determinations in payers for off-label-like comedication patterns do not block therapy, because the core indication is label-supported

LGS: incremental growth with payer and practice calibration

LGS volume depends on:

• Treatment-line positioning (starter vs adjunct use patterns)
• Evidence uptake by guideline-setting clinicians
• Payer preauthorization rules tied to seizure type, baseline frequency, and concomitant therapies

Net sales sensitivity increases in LGS because managed care often requires stricter documentation. That tends to delay or compress early net price versus Dravet, even if gross demand exists.

How do pricing, rebates, and reimbursement shape FINTEPLA’s net revenue?

Fenfluramine’s net revenue path is dominated by:

• Specialty pharmacy economics (distribution channel mix)
• Commercial payer rebates and step edits through formularies
• Patient assistance and bridge programs in rare-disease channels
• Bioscience-style pricing scrutiny due to long-term cost perception in pediatric epilepsy

What pricing pressures typically appear as sales scale?

As FINTEPLA moves from specialty centers to broader community neurology networks, payer mix shifts from:

• High-approval channels to
• Broader managed formularies with tighter rebate expectations

That commonly drives:

• Net-to-gross compression
• Greater variance between list price stability and net price declines
• Increased payer reluctance for borderline responders, affecting volume more than pricing

Where do net price risks concentrate?

The highest friction areas are:

• LGS patients with narrower eligibility windows at the payer-policy level
• Dose changes tied to tolerability or concomitant therapy adjustments
• Prior authorization documentation burden, which can cap near-term scripts

What does FINTEPLA’s competitive landscape look like by seizure type and patient segment?

FINTEPLA competes within the antiepileptic drug (AED) landscape, but market share is determined by:

• Patient eligibility for fenfluramine versus alternatives
• Expected seizure reduction and tolerability profiles
• Ongoing need for chronic therapy
• Treatment-line choice and add-on permissibility

Segment-by-segment competition

Dravet

• Competes with AEDs used in Dravet, where prescribers balance seizure control against adverse effect profiles.
• Once fenfluramine becomes established in a care plan, switching is less common unless efficacy or safety is insufficient.

LGS

• Competitors include AEDs used for LGS with various efficacy windows across seizure types.
• LGS often has more therapy switching, which increases the importance of payer access and early-response narratives.

What matters most to neurologists: responder durability vs early onset

In pediatric epilepsy, prescribers typically value:

• Speed of seizure improvement after initiation
• Long-term tolerability and caregiver adherence
• Documentation strength for reauthorization and payer renewals

Fenfluramine’s sales are therefore sensitive to real-world persistence rates and payer re-approval outcomes, not only initial uptake.

When does FINTEPLA face exclusivity and generic entry risk?

FINTEPLA’s long-term revenue ceiling is set by patent term and regulatory exclusivity timelines, which determine the earliest plausible generic or follow-on branded erosion window.

What exclusivity and patent dynamics control the “cliff”?

For a branded specialty drug like FINTEPLA, the risk stack typically includes:

• Composition-of-matter patents on fenfluramine or core formulations
• Method-of-use patents tied to Dravet and LGS dosing paradigms
• Formulation and manufacturing patents, which can block generic development even after primary composition coverage expires
• Regulatory exclusivity (for the original approval and label expansions, depending on statutory eligibility)

Because FINTEPLA’s commercial trajectory is heavily tied to pediatric indications, label expansion exclusivity (and any exclusivity tied to specific subpopulations or dosage regimens) can extend effective branded protection even if some earlier patents expire.

What generic entry scenarios are most relevant?

The risk profiles break into:

• A “complete” entry scenario where both formulation and method-of-use barriers are cleared
• A “design-around” scenario where a generic uses a different formulation approach but still must satisfy label-specified dosing or safety monitoring requirements
• An “indication carve-out” scenario where only part of the label is exposed at launch due to remaining patent coverage

The financial impact differs:

• Indication carve-outs often yield partial volume loss
• Complete entry scenarios create faster price erosion and faster share shifts

What is FINTEPLA’s FDA status and how does pathway and label scope affect commercialization?

FDA label scope affects uptake because pediatric epilepsy prescribing requires clear indication boundaries and coverage documentation.

Label-driven adoption

FINTEPLA’s commercialization depends on:

• Indication breadth across Dravet and LGS
• Whether payers accept label-defined eligibility without excessive additional criteria
• Ongoing monitoring requirements that can influence physician comfort and clinic workflows

Post-approval expansions

Any label expansion that adds patient subgroups can generate a step-up in volume, but it also increases payer education time and can raise rebate pressure if competitors target the same subsets with established payer coverage.

How do manufacturing continuity and supply affect FINTEPLA’s revenue?

For rare pediatric epilepsies, interruptions matter more than in mass-market indications because:

• Care plans are continuous
• Switching delays can directly reduce adherence and physician trust
• Specialty distribution networks depend on consistent allocation

Supply constraints typically show up as:

• Temporary demand deferrals
• Increased patient assistance complexity
• Elevated administrative burden for restarts

The revenue risk is not only lost prescriptions in the quarter of shortage, but also reduced confidence that can slow future conversion.

What financial trajectory is implied by these market dynamics?

FINTEPLA’s path is usually characterized by:

1. Launch phase: rapid physician adoption in specialized pediatric centers, high gross margin offset by elevated access and distribution costs.
2. Scale-up: broader neurologist adoption, net sales growth tempered by rebate expansion as payer mix broadens.
3. Maturity: slower growth rates driven by persistence (retention) and incremental LGS penetration.
4. Forward-looking risk: exclusivity/patent cliffs that accelerate discounting and contracting behavior ahead of potential generic erosion.

In practical business terms, the “center of gravity” for future revenue is:

• Persistence and dose continuation in responders
• LGS share gains in managed care settings
• Timing of any patent or exclusivity milestones that change payer willingness to invest in long-term coverage

Key Takeaways

• FINTEPLA growth is driven by patient capture and retention in Dravet and incremental penetration in LGS, with payer preauthorization and documentation requirements affecting net sales more than list price.
• Net revenue dynamics are shaped by specialty pharmacy channel mix and increasing managed-care rebate intensity as prescribing broadens.
• Competitive pressure is present but less about direct regimen switching in Dravet once response is established; LGS has higher switching risk and stronger payer leverage.
• The long-run revenue ceiling is governed by the patent-and-exclusivity stack, including method-of-use and formulation barriers that can delay generic erosion or limit indications at entry.

FAQs

1) What payer restrictions most directly limit FINTEPLA uptake in LGS?
Preauthorization criteria tied to baseline seizure frequency, documented failure or inadequate response to specific regimens, and renewal documentation can cap early volume and slow reauthorization, creating net sales volatility.

2) How sensitive is FINTEPLA revenue to adherence and persistence?
High. Chronic dosing means persistence drives most incremental revenue; discontinuations due to tolerability or inadequate response reduce future prescription reorders and can shift payer scrutiny at renewal.

3) Does FINTEPLA face higher competition risk in Dravet or LGS?
LGS generally has higher practical competition risk because managed care and therapy line decisions can lead to more switching among available AED options.

4) What are the most likely generic erosion scenarios for fenfluramine in the US?
Either a full-label entry if core barriers clear, or a more limited indication-entry path if method-of-use or formulation patents delay replication of key protected therapy elements.

5) How can supply disruptions translate into revenue impact for FINTEPLA?
They can cause immediate prescription deferrals, reduce patient continuity, and create restarting delays that suppress demand conversion even after supply returns.

References

1. US Food and Drug Administration. Drug Approval Packages: FINTEPLA (fenfluramine).
2. FDA Orange Book: FINTEPLA (fenfluramine) listings and patent/exclusivity references.
3. FDA Labeling for FINTEPLA (fenfluramine) prescribing information.

DrugChatter Q&A for FINTEPLA

What's the cost of fintepla for pharmacies?
Fintepla discussion by patients?
Fintepla vs its competition?
How is fintepla's price affected by insurance coverage?
Fintepla emerging insight market?